《2型糖尿病血脂指南》.pdf

Clinical Guidelines Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians Vincenza Snow, MD; Mark D. Aronson, MD; E. Rodney Hornbake, MD; Christel Mottur-Pilson, PhD; and Kevin B. Weiss, MD, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians* In an effort to provide internists and other primary care physicians for secondary prevention of cardiovascular mortality and morbidity with effective management strategies for diabetes care, the Clin- for all patients (both men and women) with known coronary ical Efficacy Assessment Subcommittee (CEAS) of the American artery disease and type 2 diabetes. College of Physicians (ACP) decided to develop guidelines on the Recommendation 2: Statins should be used for primary pre- management of dyslipidemia, particularly hypercholesterolemia, in vention against macrovascular complications in patients (both people with type 2 diabetes mellitus. The CEAS commissioned a men and women) with type 2 diabetes and other cardiovascular systematic review of the currently available evidence on the man- risk factors. agement of lipids in type 2 diabetes mellitus. The evidence review Recommendation 3: Once lipid-lowering therapy is initiated, is presented in a background paper in this issue. On the basis of patients with type 2 diabetes mellitus should be taking at least this systematic review, the CEAS developed recommendations that moderate doses of a statin. the ACP Board of Regents then approved as policy. Recommendation 4: For those patients w